AR048832A1 - Tratamiento de soporte de enfermedades hepaticas - Google Patents
Tratamiento de soporte de enfermedades hepaticasInfo
- Publication number
- AR048832A1 AR048832A1 ARP050101588A ARP050101588A AR048832A1 AR 048832 A1 AR048832 A1 AR 048832A1 AR P050101588 A ARP050101588 A AR P050101588A AR P050101588 A ARP050101588 A AR P050101588A AR 048832 A1 AR048832 A1 AR 048832A1
- Authority
- AR
- Argentina
- Prior art keywords
- treatment
- support
- hepatic diseases
- blocker
- diltiazem
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una composicion y un método para tratar un sujeto que padece una enfermedad hepática que comprende la administracion oral de una formulacion de liberacion retardada de un bloqueador de canales de calcio tal como diltiazem y tiamina, que también es un antioxidante relativamente hidrofílico, comparado con el bloqueador de los canales de calcio.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2004902151A AU2004902151A0 (en) | 2004-04-22 | Method of supportive treatment of liver disease | |
AU2004902447A AU2004902447A0 (en) | 2004-05-07 | Method of supportive treatment of liver disease |
Publications (1)
Publication Number | Publication Date |
---|---|
AR048832A1 true AR048832A1 (es) | 2006-05-31 |
Family
ID=35196732
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050101588A AR048832A1 (es) | 2004-04-22 | 2005-04-21 | Tratamiento de soporte de enfermedades hepaticas |
Country Status (9)
Country | Link |
---|---|
US (1) | US7977326B2 (es) |
EP (1) | EP1755615B1 (es) |
JP (1) | JP5519906B2 (es) |
KR (1) | KR101312010B1 (es) |
AR (1) | AR048832A1 (es) |
CA (1) | CA2563058C (es) |
HK (1) | HK1100206A1 (es) |
IL (1) | IL178366A (es) |
WO (1) | WO2005102353A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005102353A1 (en) * | 2004-04-22 | 2005-11-03 | Howard J Smith & Associates Pty Ltd | Supportive treatment of liver disease |
US20110274755A1 (en) * | 2004-04-22 | 2011-11-10 | Smith Howard J | Supportive treatment of liver disease |
AU2009298177B2 (en) | 2008-10-02 | 2013-02-07 | George Zabrecky | Methods and formulations for treating chronic liver disease |
WO2011044638A1 (en) * | 2009-10-15 | 2011-04-21 | Howard J. Smith & Associates Pty Ltd | Method of treatment of liver disease |
JP2013139391A (ja) * | 2010-04-09 | 2013-07-18 | Hokkaido Univ | ウイルス感染抑制および/または感染症治療剤 |
GB2506086A (en) | 2011-10-21 | 2014-03-19 | Abbvie Inc | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon |
CA2811250C (en) | 2011-10-21 | 2015-08-11 | Abbvie Inc. | Methods for treating hcv |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
FR3033701B1 (fr) * | 2015-03-19 | 2021-01-15 | Univ Claude Bernard Lyon | Nouvelles compositions antivirales pour le traitement de la grippe |
US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
FR3081325B1 (fr) * | 2018-05-23 | 2020-10-09 | Univ Claude Bernard Lyon | Diltiazem pour son utilisation dans le traitement des infections microbiennes |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US452555A (en) * | 1891-05-19 | Ice-pick | ||
IE56999B1 (en) | 1983-12-22 | 1992-03-11 | Elan Corp Plc | Pharmaceutical formulation |
US5002776A (en) | 1983-12-22 | 1991-03-26 | Elan Corporation, Plc | Controlled absorption diltiazem formulations |
US4917899A (en) | 1983-12-22 | 1990-04-17 | Elan Corporation Plc | Controlled absorption diltiazem formulation |
US4894240A (en) | 1983-12-22 | 1990-01-16 | Elan Corporation Plc | Controlled absorption diltiazem formulation for once-daily administration |
US5219621A (en) | 1987-10-16 | 1993-06-15 | Elan Corporation, Plc | Methods of treatment with diltiazem formulations |
US5854233A (en) * | 1993-09-08 | 1998-12-29 | Pharmacy And Therapeutic Advisory Consultancy Ltd. | Method of treating liver disease and like indications with vasodilating agents |
US5834024A (en) * | 1995-01-05 | 1998-11-10 | Fh Faulding & Co. Limited | Controlled absorption diltiazem pharmaceutical formulation |
DE19515971A1 (de) * | 1995-05-02 | 1996-11-07 | Bayer Ag | Kombinationspräparate mit vaskulärer Wirkung |
US20030049840A1 (en) | 1998-10-07 | 2003-03-13 | Demetriou Achilles A. | Cell preconditioning and cryopreservation medium |
JP3923793B2 (ja) * | 2001-11-30 | 2007-06-06 | 大日本印刷株式会社 | 画像形成方法及び画像形成物 |
DE60310282T2 (de) * | 2002-03-01 | 2007-05-10 | Dai Nippon Printing Co., Ltd. | Thermisch übertragbares Bildschutzblatt, Verfahren zur Schutzschicht-Bildung und durch das Verfahren hergestellte Aufnahme |
WO2005102353A1 (en) * | 2004-04-22 | 2005-11-03 | Howard J Smith & Associates Pty Ltd | Supportive treatment of liver disease |
-
2005
- 2005-04-21 WO PCT/AU2005/000561 patent/WO2005102353A1/en active Application Filing
- 2005-04-21 KR KR1020067024478A patent/KR101312010B1/ko not_active IP Right Cessation
- 2005-04-21 JP JP2007508672A patent/JP5519906B2/ja not_active Expired - Fee Related
- 2005-04-21 AR ARP050101588A patent/AR048832A1/es unknown
- 2005-04-21 CA CA2563058A patent/CA2563058C/en not_active Expired - Fee Related
- 2005-04-21 EP EP05733412.0A patent/EP1755615B1/en not_active Not-in-force
- 2005-04-21 US US11/547,469 patent/US7977326B2/en not_active Expired - Fee Related
-
2006
- 2006-09-28 IL IL178366A patent/IL178366A/en not_active IP Right Cessation
-
2007
- 2007-05-31 HK HK07105768.2A patent/HK1100206A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2563058A1 (en) | 2005-11-03 |
EP1755615A1 (en) | 2007-02-28 |
KR101312010B1 (ko) | 2013-09-30 |
EP1755615B1 (en) | 2013-11-27 |
JP5519906B2 (ja) | 2014-06-11 |
CA2563058C (en) | 2012-10-16 |
JP2007533667A (ja) | 2007-11-22 |
IL178366A0 (en) | 2007-02-11 |
US7977326B2 (en) | 2011-07-12 |
KR20070014185A (ko) | 2007-01-31 |
US20070292507A1 (en) | 2007-12-20 |
IL178366A (en) | 2014-01-30 |
EP1755615A4 (en) | 2009-07-29 |
WO2005102353A1 (en) | 2005-11-03 |
HK1100206A1 (en) | 2007-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR048832A1 (es) | Tratamiento de soporte de enfermedades hepaticas | |
ECSP17046065A (es) | Formas cristalinas de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenolhidrocloruro (solicitud divisional) | |
AR047993A1 (es) | Composicion farmaceutica que comprende pimobendano | |
AR050623A1 (es) | Metodo para el tratamiento del trastorno de hiperactividad de deficit de atencion | |
UY28860A1 (es) | Procedimiento para el tratamiento de trastornos premenstruales y otros trastornos sexuales femeninos | |
GT200500127A (es) | Composiciones y metodos para el tratamiento de trastorno disforico premenstrual | |
GT200400239A (es) | Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente | |
HK1156515A1 (en) | Pharmaceutical compositions and methods for accelerating wound healing | |
AR053026A1 (es) | Composiciones de anticuerpos anti factor de estimulacion de colonias de macrofagos (anti-m csf) | |
AR012264A1 (es) | Compuesto, composicion farmaceutica y metodo para obtener la composicion para prevenir o evitar una enfermedad asociada a actividad metaloproteasicaindeseada | |
AR049985A1 (es) | Tratamiento de combinacion para enfermedades malignas no hematologicas | |
AR043987A1 (es) | Composiciones farmaceuticas para administracion oral de agonistas del receptor de fosfato de esfingosina-1 | |
DE602004027936D1 (de) | Tocopherolmodifizierte therapeutische arzneimittelverbindung | |
AR109263A2 (es) | Composición que comprende moxidectina | |
ECSP088676A (es) | Pirazolquinolonas como potentes inhibidores de parp | |
BR0306870A (pt) | Composição farmacêutica oral, e, método para preparar a mesma | |
DOP2006000252A (es) | Profarmacos mutuos de glucosamina y glucosamina/anti-inflamatorio, composiciones, y metodos | |
ECSP066392A (es) | ||
ECSP11011151A (es) | Compuestos purina | |
UY29320A1 (es) | 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas, así como preparaciones farmacéuticas que las contienen | |
CR20110599A (es) | Composiciones farmacéuticamente activas que comprenden moduladores de estrés oxidativo (osm), nuevas entidades químicas, composiciones y usos | |
AR056500A1 (es) | Metodo para preparar una composicion medica | |
CL2020003143A1 (es) | Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria | |
CL2012000097A1 (es) | Compuestos derivados de 3-fenoximetilpirrolidina, inhibidores de la recaptacion de serotonina-norepinefrina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos del dolor, depresion, entre otros. | |
ES2582660T3 (es) | Sidnoniminas - inhibidores específicos de la recaptación de la dopamina y su uso en el tratamiento de los trastornos relacionados con la dopamina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |